Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HIMS
HIMS logo

HIMS News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

HIMS News

HIMS CEO Emphasizes Long-Term Execution Amid Stock Volatility

1d agostocktwits

Investment Choices: Hims & Hers vs. Teladoc

1d agoNASDAQ.COM

Investment Comparison Between Hims & Hers and Teladoc

1d agoFool

United Therapeutics Corp Sees Surge in Options Trading Volume

1d agoNASDAQ.COM

Hims & Hers Secures $400M Financing Agreement with JPMorgan Chase

6d agostocktwits

FDA Revives Advisory Committee Meetings for Drug Approvals

6d agoseekingalpha

HIMS Faces Negative Impact from FDA's Peptide Recommendation

6d agoNewsfilter

FDA Challenges Seven Popular Peptides Amid Safety Concerns

6d agostocktwits

HIMS Events

06/30 11:00
Hims and Hers Health Shares Up 1.23% to $33.80
Moderately bullish activity in Hims and Hers Health (HIMS), with shares up 41c, or 1.23%, near $33.80. Options volume relatively light with 20k contracts traded and calls leading puts for a put/call ratio of 0.29, compared to a typical level near 0.33. Implied volatility (IV30) is higher by 3.8 points near 107.03,in the top quartile of the past year, suggesting an expected daily move of $2.28. Put-call skew steepened, indicating increased demand for downside protection.

HIMS Monitor News

Hims & Hers Faces Challenges from FDA's Peptide Recommendation

Jul 07 2026

Hims & Hers Secures $400M Financing Agreement with JPMorgan Chase

Jul 06 2026

Hims & Hers partners with Novo Nordisk to boost weight-loss drug offerings

Jul 01 2026

Hims & Hers Partners with Novo Nordisk to Boost Weight-Loss Drug Offerings

Jun 30 2026

Hims partners with Novo Nordisk to boost weight-loss drug offerings

Jun 26 2026

Hims & Hers Health CMO Plans Share Sale Amid Positive Market Trends

Jun 25 2026

Hims & Hers Partners with Novo Nordisk, Boosting Stock Momentum

Jun 18 2026

Hims & Hers Stock Rises on Peptide Market Optimism

Jun 17 2026

HIMS Earnings Analysis

No Data

No Data

People Also Watch